Señales en vivo de MREO | Maximiza tus Ganancias con Getagraph.com

COMPRAR 118864 min ago

@ $3.74

Emitido: 14 feb 2024 @ 12:33

Retorno: -17.11%

Señal anterior: feb 14 - 11:06

Señal anterior: Vender

Retorno: 0.00 %

Live Chart Being Loaded With Signals

Commentary (6 may 2024 @ 16:00):

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally...

Stats
Volumen de hoy	834 694
Volumen promedio	1.21M
Capitalización de mercado	434.18M
EPS	$0 ( 2024-03-26 )
Próxima fecha de ganancias	( $0 ) 2024-05-21
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-15.50
ATR14	$0.0100 (0.32%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-08	Ekblom Anders	Buy	45 000	Share Options (Right to buy)
2024-02-08	Ekblom Anders	Buy	19 471	Deferred Restricted Stock Units
2024-02-08	Jacquet Pierre	Buy	45 000	Share Options (Right to buy)
2024-02-08	Jacquet Pierre	Buy	15 553	Deferred Restricted Stock Units
2024-02-08	Yoskowitz Marc J	Buy	45 000	Share Options (Right to buy)

INSIDER POWER
-60.62
Last 97 transactions
Buy: 2 158 393 \| Sell: 9 188 547

Volumen Correlación

Largo: -0.01 (neutral)

Corto: 0.72 (moderate)

Signal:(66.297) Neutral

Mereo BioPharma Group plc Correlación

10 Correlaciones Más Positivas
CFBK	0.888
SLNO	0.887
PBPB	0.885
PROV	0.873
ECOR	0.867
ARDX	0.865
RBKB	0.861
ISTR	0.854
CXDO	0.854
CPLP	0.851

10 Correlaciones Más Negativas
OSMT	-0.878
PFBI	-0.858
HCM	-0.847
MLVF	-0.847
IQ	-0.844
RMRM	-0.843
BFRI	-0.838
COCO	-0.833

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Mereo BioPharma Group plc Correlación - Moneda/Commodity

0.65
( moderate )

0.72
( moderate )

0.00
( neutral )

0.59
( weak )

-0.60
( weak negative )

Mereo BioPharma Group plc Finanzas

Annual	2023
Ingresos:	$10.00M
Beneficio Bruto:	$7.43M (74.26 %)
EPS:	$0

FY	2023
Ingresos:	$10.00M
Beneficio Bruto:	$7.43M (74.26 %)
EPS:	$0

FY	2022
Ingresos:	$1.51M
Beneficio Bruto:	$571 000 (37.89 %)
EPS:	$-0.280

FY	2021
Ingresos:	$36.46M
Beneficio Bruto:	$18.56M (50.89 %)
EPS:	$0.159

Financial Reports:

No articles found.

Mereo BioPharma Group plc

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.